ClinicalTrials.gg
RecruitingNCT07945613Updated Nov 18, 2026

IoC2-Guided Remifentanil Titration for Early Postoperative Pain After Laparoscopic Cholecystectomy

An interventional study of IoC2-guided remifentanil titration and Standardized titration with IoC2 concealed in Pain, sponsored by Yi Duan. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Yi Duan · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 246 studies in Pain with a site in China — 65 open to participants now, 71 under way, 2 of them phase 3. Pain · China.

Planned enrollment
33rd of 211
330 · median 120
Started
2026
with 23 others
No phase
116 of 246
39 open now
Primary completion
2028-07
later than 65 of 70 live
Registered
246th of 246
by date

Among the 246 studies in Pain with a site in China, this one is the 33rd largest by planned enrollment of the 211 interventional ones that give a count, is one of 24 that started in 2026, is one of 116 with no phase, reaches primary completion later than 65 of the 70 other live ones, and was the 246th registered.

Pain

10,071 studies on the registry are indexed under Pain; 1,649 are open to participants now.

Browse Pain studies →

Open to participants now

65 of the 246 studies in Pain with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 65 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 246 studies in Pain with a site in China, or all of them as a file.
02

Study summary

This is a single-centre, patient- and outcome-assessor-blinded, active-controlled, randomized superiority trial. The study will test whether remifentanil titration guided by the Index of Consciousness 2 (IoC2) displayed on the Angel-6000 monitor reduces early postoperative pain during the first 60 minutes after post-anaesthesia care unit (PACU) arrival compared with standardized remifentanil titration with IoC2 concealed, in adults undergoing elective laparoscopic cholecystectomy for benign gallbladder disease.

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-75 years, of any sex
  2. (ASA) physical status I-III
  3. Elective standard three- or four-port laparoscopic cholecystectomy under general anaesthesia for benign gallbladder disease (gallstones, chronic cholecystitis, or gallbladder polyps)
  4. Planned total intravenous anaesthesia, with the surgeon expecting completion through a standard laparoscopic approach
  5. Ability to understand the 0-10 NRS and follow-up procedures and to complete assessments in Chinese
  6. Written

Exclusion criteria

Exclusion Criteria:

  1. Emergency surgery; active acute cholecystitis, cholangitis, or acute pancreatitis; planned open, single-port, robotic, common-bile-duct exploration, or combined surgery; or expected postoperative mechanical ventilation
  2. Persistent preoperative moderate-to-severe pain (resting NRS ≥4) or daily opioid use for more than 7 days during the preceding 30 days
  3. Severe cognitive, psychiatric, language, hearing, or communication impairment that precludes reliable pain assessment
  4. Severe cardiac, pulmonary, hepatic, or renal dysfunction, or another condition that in the investigator's judgement precludes standardized anaesthesia
  5. to propofol, remifentanil, rocuronium, acetaminophen, a non-steroidal anti-inflammatory drug, dexamethasone, local anaesthetic, or the planned rescue medication
  6. Pregnancy or breastfeeding
  7. Frontal skin injury, severe adhesive allergy, or another condition preventing electrode placement
  8. Participation within the previous 3 months in another interventional study that could affect the primary outcome
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
330 participants (estimated)

Study arms

  • Experimental
    Experimental group

    IoC2-guided remifentanil titration

    Procedure: IoC2-guided remifentanil titration

  • Active comparator
    Control Group

    Standardized titration with IoC2 concealed

    Procedure: Standardized titration with IoC2 concealed

Interventions

  • ProcedureIoC2-guided remifentanil titration

    IoC2 displayed on Angel-6000 monitor; target range 35-45; titration step 0.5 ng/mL effect-site concentration

  • ProcedureStandardized titration with IoC2 concealed

    Standardized titration with IoC2 concealed

06

What researchers measure

Primary outcomes

  1. NRS(0-10 numerical rating scale) score

    Time frame: 60 minutes

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jul 2028, 22 months after the start.

Of 3,746 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 22 months is above that.

Counting every sponsor, half of 3,845 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartActual
Sep 18, 2026
Primary completionEst.
Jul 2028
CompletionEst.
Jul 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07945613
Lead sponsor
Yi Duan
Responsible party
Yi Duan (Director, Beijing Tsinghua Chang Gung Hospital) — Sponsor-investigator
First posted
Nov 18, 2026
Start date
Sep 18, 2026
Primary completion
Jul 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Yi Duan
Contact
dya01610@btch.edu.cn
13810385311 ext. 86

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion